Sionna Therapeutics, Inc. - Common Stock (SION)

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION) investors concerning the Company’s possible violations of federal securities laws.

The Law Offices of Frank R. Cruz announces an investigation of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Shareholder rights law firm Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) to determine whether certain Sionna Therapeutics officers and directors violated securities laws and breached fiduciary duties to shareholders.

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or “the Company”) (NASDAQ: SION) for violations of the securities laws.

The drugmaker should significantly mitigate its most important risk as it develops new products.

Roughly 90% of Sionna Therapeutics (SION) market value was erased after the Company released Phase 2a PreciSION CF results for SION-719, representing a decline of approximately $40 per share from the stock’s recent trading levels. If you held SION shares and suffered a loss, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular session. The market value of their outstanding shares is at $9.5 million. Sionna Therapeutics (NASDAQ:SION) shares rose

Sionna Therapeutics (NASDAQ:SION) said its PreciSION CF Phase 2a proof-of-concept study of SION-719 added to Trikafta did not meet its key activity endpoint, prompting the company to discontinue development of SION-719 as an add-on to standard of care for cystic fibrosis. The company also reported

SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard of care

This risk is weighing on the stock.

PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care is on track for topline data summer of 2026

WALTHAM, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in the following upcoming investor events:

WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20th, 2026, at 2:05 p.m. ET.

Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of 2026

This biotech innovator in cystic fibrosis therapies reported a notable insider sale amid a year of standout stock performance.

Topline data is on track for anticipated readout in the summer of 2026

WALTHAM, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14th, 2026.

This biotech innovator in cystic fibrosis therapies reported a notable insider sale, as disclosed in recent SEC filings.

This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway.

This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.

This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing.

Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated in mid-2026

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events: